|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Consensus on the definition of colorectal anastomotic leakage: A modified Delphi study显示文摘BACKGROUND Despite the emerging knowledge about colorectal anastomotic leakage(CAL)through the increasing number of clinical and experimental studies, there is no generally accepted definition of CAL. Because of the wide variety of definitions used in literature, comparison of study outcomes and quality of care is complicated.AIM To reach consensus on the definition of CAL using a modified Delphi method.METHODS The RAND/UCLA appropriateness method was used. The expert panel consisted of international colorectal surgeons and researchers who had published three or more articles about CAL. The consensus process consisted of two online distributed questionnaires and a third round with a recommendation. In the questionnaires participants were asked to rate the appropriateness of statements using a 1-9 Likert scale. Consensus was defined as a panel median between 1-3 or 7-9 without disagreement. In the final round a recommendation was formed regarding the definition of CAL and the expert panel was asked if they agreed or disagreed.RESULTSTwenty-three authors participated in the first round and twenty-one finished the second round. After two rounds consensus was reached on 37 items(80%) in nine different categories. The International Study Group of Rectal Cancer definition is the most frequently advised general definition by our panel. Consensus was reached regarding the clinical symptoms of CAL, which serum markers contributes to the suspicion of CAL, which radiological and perioperative findings should be considered as CAL, which grading system is appropriate and if there should be a range of postoperative days in the definition. Eventually, 19 experts completed all three rounds of which 16(84%) agreed with our final recommendations for the definition of CAL.CONCLUSION A consensus-based recommendation for the definition of CAL was formed using our modified Delphi method that can be widely incorporated in the field. | Claire PM van Helsdingen Audrey CHM Jongen Wouter J de Jonge Nicole D Bouvy Joep PM Derikx | 2020 | World Journal of Gastroenterology2020，26，23： | 3 |
| 2 | Monolith in catalytic oxidation 显示文摘 | John W J Joep C Van G | 1999 | Catalysis Today1999，47，： | 1 |
| 3 | The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy显示文摘 | Mina C Hosseinipour Joep JG van Oosterhout Ralf Weigel Sam Phiri Debbie Kamwendo Neil Parkin Susan A Fiscus Julie AE Nelson Joseph J Eron Johnstone Kumwenda | 2009 | AIDS2009，，9： | 1 |
| 4 | An adventure in catalysis: the story of the BP Fis- cher Tropsch catalyst from laboratory to full-scale demonstration in Alaska显示文摘 | Joep J H M | 2003 | Topics in Catalysis2003，26，1： | 1 |
| 5 | An adventure in catalysis: the story of the BP Fischer- Tropsch catalyst from laboratory to full-scale demonstration in Alaska显示文摘 | Joep J H M | 2003 | Topics in Catalysis2003，26，1： | 1 |
| 6 | A pilot study on potential new plasma markers for diagnosis of acute appendicitis显示文摘 | GEERTJE T JOEP P M FRED J P | 2011 | Am J Emerg Med2011，29，3： | 1 |
| 7 | An adventure in catalysis:The story of the BP F-T catalyst from laboratory to full-scale demonstration in Alaska显示文摘 | JOEP J FREIDEA F GAMLIN T | 2003 | Topics in Catalysis2003，26，14： | 1 |
| 8 | Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial显示文摘 | Marjolein YV Homs Ewout W Steyerberg Wilhelmina MH Eijkenboom Hugo W Tilanus Lukas JA Stalpers Joep FWM Bartelsman Jan JB van Lanschot Harm K Wijrdeman Chris JJ Mulder Janny G Reinders Henk Boot Berthe MP Aleman Ernst J Kuipers Peter D Siersema | 2004 | The Lancet2004，，9444： | 1 |
| 9 | The versatile use of exhaled volatile organic compounds in human health and disease显示文摘 | Agnes W Boots Joep J B N van Berkel Jan W Dallinga Agnieszka Smolinska Emile F Wouters Frederik J van Schooten | 2012 | Journal of Breath Research2012，，2： | 1 |
| 10 | A new hybrid filter to dampen resonances and compensate harmonic currents in industrial power systems with power factor correction equipment显示文摘 | Dirk D Joep J Rik W D D | 2001 | IEEE Trans on Power Electronics2001，16，6： | 1 |
| 11 | A new hybrid filter to dampen resonances and compensate harmonic currents in industrial power systems with power factor correction equipment显示文摘 | DIRK D JOEP J RIK W | 2001 | IEEE Trans On power electronics2001，16，6： | 1 |
| 12 | A new hybrid filter to dampen resonances and compensate harmonic currents in industrial power systems with power factor correction equipment显示文摘 | Dirk D Joep J Rik W | 2001 | IEEE Transactions on Power Electronics2001，16，6： | 1 |
| 13 | Taxane resistance in breast cancer: A closed HER2 circuit?显示文摘 | Joep P.J. de Hoon Jürgen Veeck Birgit E.P.J. Vriens Tim G.A. Calon Manon van Engeland Vivianne C.G. Tjan-Heijnen | 2012 | BBA - Reviews on Cancer2012，，2： | 1 |
| 14 | 家族性高胆固醇血症大家系在两个世纪中的死亡率:家系死亡率研究显示文摘目的 :评估未经治疗的无冠状动脉疾病的家族性高胆固醇血症所有原因的死亡率。设计 :家系死亡率研究。背景 :荷兰的一个大家系 ,其宗亲源自 19世纪一对夫妇。先证者 :家族中所有超过 2 0岁且有 5 0 %可能性携带家族性高胆固醇血症突变基因者。主要结果测定指标 :各种原因的死亡率。结果 :分析自 6 95 0人年的 2 5 0人中共死亡的70人。突变基因携带者的死亡率在 19世纪和 2 0世纪早期并未升高 ,1915年后开始升高 ,1935~196 4年达到高峰 (标准化死亡率比 1 78,95 %可信区间 1 13~ 2 76 ,P =0 0 0 3) ,以后下降。家系的两大分支间死亡率有显著性差异 (相对危险性3 2 6 ,95 %可信区间 1 74~ 6 11;P =0 0 0 1)。结论 :家族性高胆固醇血症患者间的死亡危险性差异显著。这种时间上及家系的不同分支间的巨大差异表明环境因素与基因有强大的相互作用。有必要进一步研究以识别那些极高危并需早期和强力预防措施的家族性高胆固醇血症患者。 | Eric J G Sijbrands Rudi G J Westendorp Joep C Defesche Paul H E M deMeier Augustinus H M Smelt John J P Kastelein 马志毅 | 2002 | 英国医学杂志中文版2002，5，3： | 0 |
| 15 | Development of a CO_2 Tolerant Fischer-Tropsch Catalyst:from Laboratory to Commercial-Sca1e Demonstration in Alaska显示文摘This article describes the development of BP's Fischer-Tropsch catalyst, used for the conversion of carbon monoxide and hydrogen into liquid hydrocarbons. It covers the 18 year period from the early eighties, when laboratory scale preparations and micro-reactors were heavily used, right through to the present day with the commercial scale manufacture and proving of the finished catalyst in BP's new $86 million gas to liquids demonstration facility in Nikiski, Alaska. Extensive performance testing and scale-up experiments have been successfully carried out, all proof that a laboratory preparation can indeed be translated into a commercial manufacturing process. In addition, the resulting catalyst does not only meet the process design targets, but also exhibits enhanced stability and is tolerant to carbon dioxide.Above all, a commercial scale, fixed bed Fischer-Tropsch catalyst is now available and ready for licensing.Manufacturing procedures and quality control have all been successfully detailed and transferred to the commercial manufacturer. | Joep J H M Font Freide Tim D Gamlin J Richard Hensman Barry Nay Christopher Sharp | 2004 | Journal of Natural Gas Chemistry2004，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员